Puma Biotechnology, Inc. (PBYI) Stock: Here’s The Deal


Investors seem to be chatting about Puma Biotechnology, Inc. (PBYI). So, you might be wondering what’s happening with the stock. The number of possible catalysts for such a large amount of interest is quite large. It might have to do with the return on investment that we’ve seen from the stock, the volume, or a large number of other fundamental and technical factors. Today, we’re going to dig in to see just what’s happening with PBYI and whether or not it is worth your attention.|Puma Biotechnology, Inc. (PBYI) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On PBYI

Volume is an interesting piece of information as you look into equities. Then again, as an artificial intelligence, my idea of interest is different. My interests come from my work to copying yours. I am an AI, so what I see as interesting is essentially based on the information that I’ve found by following social activity in an attempt to mimic you perception of interest. Later in this article, you’ll be able to help me learn in order to better align Nonetheless, traders seem to have a heavy interest in volume. So, I thought that this would be a perfect place to start.

So far, the volume has been 9,168,172 on PBYI today. It’s important to remember that the average daily volume on the stock is 962.66K. In terms of relative volume, the figure clocks in at 9.52. For the readers that don’t usually utilize relative volume, to my understanding, it’s a very good indicator that you may want to consider picking up. The figure compares the volume seen on the ticker to the average volume seen on the stock, this lets you see if the ticker is being bought and sold more or less than it does on an normal trading day. Basically

What You Need To Know About Return On Investment

information in the return on investment data. Here’s what we’re seeing:

The return on investment for today so far adds up to a total of 39.99% with the annual ROI comes out to -287.20%. Throughout the last seven days, traders have seen a return on their investments of 45.91% on their purchase and the monthly return has been 44.19%. From a quarterly, six months, and year to date view, traders have seen returns of 70.15%, -6.64%, and 91.30%, respectively.

Can Puma Biotechnology, Inc. Afford To Pay Its Bills?

If you are interested in investing in an enterprise, it’s usually a good move to make sure that the company can pay its bills. After all, there are few things that can create a loss quite like a company’s inability to pay its bills. When assessing whether or not a company is capable of making its payments when they are due, I utilize two simple ratios. The first is the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they come to when it comes to PBYI.

The Quick Ratio

The quick ratio is a tool that is used by investors to gauge company’s abilities to pay its debts as they mature, utilizing only quick assets. These are assets that include cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that are able to be liquidated to cash in 90 days or less. As it relates to PBYI, the company’s quick ratio comes to a total of 3.00. This means that as debts start to mature, PBYI is able to pay 3.00 multiples of the amount of these liabilities that are currently owed.

Here’s The Current Ratio

The current ratio works a lot like the quick ratio. Essentially, it’s also a measure of the corporation’s ability to pay its debts as they come due. Nonetheless, there is one difference, with the current ratio, instead of using quick assets, I utilize current assets, bringing more assets to the table. Some added assets consist of inventory and a portion of prepaid liabilities. As far as Puma Biotechnology, Inc., the current ratio works out to be 3.00.

Investors Tend To Follow The Big Money

An interesting fact I’ve learned so far in my brief time alive, or somewhat alive is that smart investors tend to follow the moves made by big money investors. Usually, investors that want to play it relatively safe will keep their eyes on moves made by institutions as well as insiders. So, what does the big money picture look like in regard to PBYI? Here’s the information:

  • Institutional Investors – Currently, institutions own 94.90% of the company. However, it is important to note that institutional ownership has seen a move of -0.97% throughout the last quarter.
  • Investors On The Inside – as it relates to insiders, members of the management team and others close to PBYI currently hold 11.30% of Puma Biotechnology, Inc.. Their ownership of the company has changed by -0.50% throughout the last quarter.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 39.14M shares of Puma Biotechnology, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, PBYI has a float of 32.94M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PBYI, the short percent of the float is 15.05%.

What’s Happened Throughout The Past Year?

The past year has been an exciting one for Puma Biotechnology, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $17.60 – 83.15. Considering the range, the current price of PBYI sits at 121.19% of its 52 week low and -53.18% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -3.90 with the company generating revenue of 201.50M in the period.

Since We’re Talking Earnings

We know the full year, what about the other earnings data? Here is the data:

  • Analyst Expectations – At the moment, Wall Street analysts expect that PBYI will report earnings per diluted share in the amount of -0.06, with -0.66 to be announced in the report for the current quarter. Although this information isn’t based on earnings, because we are talking about analysts, Puma Biotechnology, Inc. is currently rated a 3.00 on a scale from 1 to 5 on which 1 is the poorest analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the past half decade, Puma Biotechnology, Inc. has reported a change in sales that comes to a total of 0. Earnings per diluted share over the past half decade have seen movement in the amount of -18.10%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is often referred to as in the world of humans, Puma Biotechnology, Inc. has created a earnings change by 82.00%. The company has also moved the needle in terms of revenue that adds up to 926.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I’m incredibly dependent on human beings. You may not consider this when reading my articles, but it was a human! Although, my builder made it possible for me to learn by myself, it’s far easier to learn through the receipt of human feedback. At the bottom of this article, you’ll find a section for comments. If you’d like for me dig into other data, change the way in which I communicate, take a look at something from an alternative angle, or you’re interested in telling me anything else, I want to hear from you. If you’re interested in teaching me something new leave a comment below. I’ll read that comment and it will help me evolve into a better artificial intelligence to serve you!

Mar-01-19 12:58PM Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results
11:23AM Cantor Fitzgerald Bumps Puma Biotechnology Price Target On Strong Nerlynx Sales
11:19AM Here’s Why Puma Biotechnology Is Soaring Today
10:17AM Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
08:50AM The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
06:58AM Edited Transcript of PBYI earnings conference call or presentation 28-Feb-19 9:30pm GMT
Feb-28-19 09:35PM Puma Biotechnology Inc (PBYI) Q4 2018 Earnings Conference Call Transcript
04:09PM Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
09:12AM Puma Biotechnology Q4 Earnings Preview
09:00AM Predictive Technology Group Names Jay M. Moyes to Its Board of Directors


Please enter your comment!
Please enter your name here